A phase II trial of PTK-787 (PTK/ZK) in recurrent or progressive meningiomas

被引:7
|
作者
DeBoer, R. [1 ]
Grimm, S. A. [1 ]
Chandler, J. [1 ]
Gallot, L. [1 ]
Kennedy, S. [1 ]
Burns, K. [1 ]
Rice, L. [1 ]
Cabreza, C. [1 ]
Muro, K. [1 ]
Raizer, J. J. [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
D O I
10.1200/jco.2008.26.15_suppl.2060
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2060
引用
收藏
页数:1
相关论文
共 50 条
  • [1] A PHASE II TRIAL OF PTK787/ZK 222584 (PTK787) IN RECURRENT OR PROGRESSIVE MENINGIOMAS
    Raizer, Jeffrey
    Grimm, Sean
    Chandler, James
    Muro, Kenji
    Rice, Laurie
    McCarthy, Katie
    Mrugala, Maciej
    Johnston, Sandra K.
    Chamberlain, Marc
    [J]. NEURO-ONCOLOGY, 2010, 12 : 50 - 50
  • [2] A PHASE II TRIAL OF PTK787/ZK 222584 (PTK787) IN RECURRENT OR PROGRESSIVE MENINGIOMA
    Deboer, Rebecca
    Grimm, Sean
    Chandler, James
    Gallot, Lilia
    Kennedy, Shannon
    Burns, Kimberly
    Rice, Laurie
    Cabreza, Czarina
    Muro, Kenji
    Raizer, Jeffrey
    [J]. NEURO-ONCOLOGY, 2008, 10 (05) : 824 - 824
  • [3] A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas
    Raizer, Jeffrey J.
    Grimm, Sean A.
    Rademaker, Alfred
    Chandler, James P.
    Muro, Kenji
    Helenowski, Irene
    Rice, Laurie
    McCarthy, Katie
    Johnston, Sandra K.
    Mrugala, Maciej M.
    Chamberlain, Marc
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2014, 117 (01) : 93 - 101
  • [4] A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas
    Jeffrey J. Raizer
    Sean A. Grimm
    Alfred Rademaker
    James P. Chandler
    Kenji Muro
    Irene Helenowski
    Laurie Rice
    Katie McCarthy
    Sandra K. Johnston
    Maciej M. Mrugala
    Marc Chamberlain
    [J]. Journal of Neuro-Oncology, 2014, 117 : 93 - 101
  • [5] A phase II trial of PTK787/ZK 222584 (PTK787) in recurrent high-grade meningioma.
    Grimm, S. A.
    Chamberlain, M. C.
    Chandler, J.
    Muro, K.
    Rice, L.
    McCarthy, K.
    Rademaker, A.
    Helenowski, I. B.
    Johnston, S. K.
    Mrugala, M. M.
    Raizer, J. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM).
    Conrad, C
    Friedman, H
    Reardon, D
    Provenzale, J
    Jackson, E
    Serajuddin, H
    Laurent, D
    Chen, B
    Yung, WKA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 110S - 110S
  • [7] A phase I/II trial of single-agent PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM)
    Yung, W. K. Alfred
    Friedman, H.
    Reardon, D.
    Provenzale, J.
    Jackson, E.
    Serajuddin, H.
    Laurent, D.
    Chen, B.
    Conrad, C.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 207 - 207
  • [8] A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGF-R TK inhibitor in patients with recurrent GBM.
    Friedman, HS
    Yung, WA
    Jackson, E
    Provenzale, J
    Leeds, N
    Conrad, C
    Walker, A
    Henry, A
    Laurent, D
    Dugan, M
    [J]. CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3665S - 3665S
  • [9] A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temazolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM).
    Reardon, D
    Friedman, H
    Yung, WKA
    Brada, M
    Conrad, C
    Provenzale, J
    Jackson, E
    Serajuddin, H
    Chen, B
    Laurent, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 110S - 110S
  • [10] A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a multi-VEGF receptor tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme
    Resardon, David
    Friedman, H.
    Brada, M.
    Conrad, C.
    Provenzaie, J.
    Jackson, E.
    Serajuddin, H.
    Chen, B.
    Laurent, D.
    Yung, W.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 207 - 207